Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
1(13%)
Results Posted
40%(2 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_1
6
75%
Ph phase_2
2
25%

Phase Distribution

6

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
6(75.0%)
Phase 2Efficacy & side effects
2(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(5)
Terminated(2)

Detailed Status

Completed5
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
71.4%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (75.0%)
Phase 22 (25.0%)

Trials by Status

active_not_recruiting113%
terminated225%
completed563%

Recent Activity

1 active trials
Showing 5 of 8
active_not_recruitingphase_2

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

NCT02711553
completedphase_1

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

NCT02791334
terminatedphase_2

Merestinib In Non-Small Cell Lung Cancer And Solid Tumors

NCT02920996
terminatedphase_1

Merestinib on Bone Metastases in Subjects With Breast Cancer

NCT03292536
completedphase_1

Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT03125239
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT02711553Phase 2

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Active Not Recruiting
NCT02791334Phase 1

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

Completed
NCT02920996Phase 2

Merestinib In Non-Small Cell Lung Cancer And Solid Tumors

Terminated
NCT03292536Phase 1

Merestinib on Bone Metastases in Subjects With Breast Cancer

Terminated
NCT03125239Phase 1

Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed
NCT03027284Phase 1

A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer

Completed
NCT02745769Phase 1

A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

Completed
NCT02779738Phase 1

A Study of Merestinib (LY2801653) in Healthy Participants

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8